EUTOS Score for Chronic Myelogenous Leukemia (CML)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰۰ • واحد: percentage
حداقل ۰ — حداکثر ۳۰ • واحد: cm
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–87
- High Risk88–1000
The EUTOS Score for Chronic Myelogenous Leukemia (CML) calculates predicting outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Key inputs include basophil percentage. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.
Clinical Indication
The EUTOS Score for Chronic Myelogenous Leukemia (CML) is indicated for bedside clinical practice to support Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase inhibitor treatments. Predicts probability of complete cytogenetic response at 18 months and progression-free survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Spleen size estimation is subjective but included in validation studies.
EUTOS Score = (7 × basophil percentage) + (4 × spleen size in cm)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| basophil_percentage | float | Yes | Basophils as percentage of peripheral blood leukocytes(percentage) |
| spleen_size_cm | float | Yes | Spleen size palpable below left costal margin(cm) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–87 | Low Risk | Low risk for CML progression |
| 88–1000 | High Risk | High risk for CML progression |
Evidence-Based References (EBM)
- Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038.DOI: 10.1182/blood-2010-12-319038
- Hoffman R, Nagler A, Keating A, Kamel-Reid S, Lipton JH. The EUTOS score predicts outcome in CML patients treated with nilotinib front-line. Blood. 2012 Dec 6;120(23):4684; author reply 4684-5. doi: 10.1182/blood-2012-08-449249.DOI: 10.1182/blood-2012-08-449249
- Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 update. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569.DOI: 10.1182/blood-2013-05-501569